Abivax develops innovative treatments modulating the body’s natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer.
As a clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to optimize and develop drug candidates to treat ulcerative colitis, Crohn’s disease, rheumatoid arthritis, and other inflammatory diseases (ABX464) as well as liver cancer (ABX196). Our mission is to utilize Abivax’s drug development platforms to bring innovative and effective solutions to patients in these therapeutic areas with significant unmet needs.
Abivax leverages three technology platforms for drug discovery:
Modulation of RNA Biogenesis: ABX464
Immune Enhancement: ABX196
Polyclonal Antibody: ABX544
In addition, Abivax is advancing multiple preclinical candidates for the treatment of additional inflammatory diseases as well as viral infections such as Respiratory Syncytial Virus (RSV), Dengue, and Influenza from its Modulation of RNA Biogenesis platform.
Abivax’s most advanced compound, ABX464, has completed Phase 2a and Phase 2b clinical induction trials, investigating its potent anti-inflammatory effect and its potential ability to treat ulcerative colitis (UC). The corresponding follow-on open label extension studies are ongoing. Further, a Phase 2a clinical trial to treat rheumatoid arthritis is ongoing and a pivotal Phase 2b/3 clinical trial in Crohn’s disease is in preparation with first patient enrollment expected to start in Q3 2021.